MAP4343

DRUG2 trials

Sponsors

Mapreg, The Scripps Research Institute

Conditions

Alcohol Use DisorderDepression

Phase 2

RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode

CompletedNCT03870776

MapregDepression

Start: 2019-06-01End: 2024-11-07Updated: 2026-03-31

MAP4343 Treatment for Alcohol Use Disorder

WithdrawnNCT04157114

The Scripps Research InstituteAlcohol Use Disorder

Start: 2021-12-31End: 2022-12-31Updated: 2022-03-11